The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

including migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven Pharmaceutical) and cancer drug Padcev ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

Days after Pfizer Inc. pulled the plug on its oral GLP-1 candidate danuglipron, Eli Lilly and Co. aired positive top-line data from the phase III trial called Achieve-1 testing orforglipron vs.